Every year, the American Society of Clinical Oncology (ASCO) Annual Meeting brings together cancer researchers, oncologists, and advocates to discuss the latest research. Some studies presented at ASCO may eventually change how prostate cancer is treated. Others help answer practical questions that patients and families have been asking for years.
Several prostate cancer studies are drawing attention because they focus on issues patients care deeply about, including whether treatment can be intensified earlier for high-risk disease, whether some patients may safely take treatment breaks, how genetic testing may guide treatment choices, and how side effects like thinking and memory changes should be considered.
Here are five prostate cancer studies patients and advocates should be paying attention to at ASCO 2026.
1. PROTEUS: Could earlier treatment improve outcomes for high-risk localized prostate cancer?
One of the biggest prostate cancer studies at ASCO 2026 was PROTEUS, a phase III trial looking at whether adding apalutamide (Erleada), a hormone-blocking therapy, to androgen deprivation therapy (ADT) before and after prostate surgery can improve outcomes for patients with high-risk localized or locally advanced prostate cancer. PROTEUS was selected for a high-profile plenary presentation at ASCO 2026, which signals that many experts are watching it closely.
This study is especially important because these patients are still being treated with the goal of cure, but they also face a higher risk that the cancer could return. Researchers are examining whether intensifying treatment around the time of surgery can improve important outcomes, including whether cancer can be cleared more completely at surgery and whether patients remain free from metastatic disease longer.
For patients with high-risk prostate cancer who are considering surgery, this study may shape future conversations about whether treatment should begin before surgery, continue after surgery, or remain focused on surgery alone.
Key takeaways: Results revealed that adding apalutamide to ADT before and after prostate surgery significantly improved outcomes for this patient population. Patients receiving apalutamide were nearly 10 times more likely to have little or no cancer remaining at surgery (8.9% vs. 1.0%) and experienced a 20% reduction in the risk of metastasis or death. At five years, 78.2% of patients in the apalutamide group remained free of metastatic disease compared with 73.5% of those receiving ADT alone. Based on these findings, researchers concluded that apalutamide plus ADT alongside surgery may represent a new standard of care for high-risk prostate cancer.
2. TALAPRO-3: Bringing targeted therapy earlier for some metastatic patients
TALAPRO-3 studied talazoparib, a PARP inhibitor, combined with enzalutamide in patients with metastatic castration-sensitive prostate cancer (mCSPC) whose tumors have homologous recombination repair, or HRR, gene alterations.
This matters because PARP inhibitors are targeted therapies that may be especially useful for patients whose cancers have certain DNA repair mutations, including BRCA-related alterations. The key question is whether using a PARP inhibitor earlier, while the cancer is still hormone-sensitive, can delay cancer progression compared with enzalutamide alone.
For patients with mCPSC, TALAPRO-3 reinforces why genetic and biomarker testing are becoming increasingly important. The study may also raise new questions about treatment sequencing, including whether some patients should receive targeted therapy earlier rather than saving it for later stages of disease. The trial met its primary endpoint of improved radiographic progression-free survival, and ASCO provides a closer look at the data.
Key takeaways: The combination of talazoparib and enzalutamide significantly delayed cancer progression compared with enzalutamide alone, reducing the risk of radiographic progression or death by about 52%. The benefit was seen in both patients with BRCA mutations and those with other HRR gene alterations. While overall survival data are still immature, early results showed a trend toward fewer deaths in the talazoparib group. The most frequent side effects included anemia, fatigue, low neutrophil counts, weakness, and low white blood cell counts. Anemia was especially common and was sometimes severe, with some patients needing dose changes, supportive care, blood transfusions, or stopping talazoparib. These side effects were generally expected based on what is already known about these medications, but they are still important and can meaningfully affect how patients feel during treatment.
3. A-DREAM: Can some patients safely take a break from hormone therapy?
Many men with metastatic hormone-sensitive prostate cancer (mHSPC) receive long-term ADT, often combined with newer androgen receptor pathway inhibitors. These treatments can help control the cancer, but they can also affect quality of life in major ways, including fatigue, sexual function, bone health, mood, metabolism, and overall energy.
The A-DREAM study looked at whether patients who respond exceptionally well to treatment may be able to safely interrupt ADT for a period of time. This is the kind of question many patients care about deeply. Living longer matters, but so does living well. If treatment breaks can be offered safely to carefully selected patients, it could become an important quality-of-life conversation.
Key takeaways: Results suggest that some patients with mHSPC who respond exceptionally well to hormone therapy may be able to safely take a break from treatment. At 18 months after stopping therapy, 41% of patients remained off treatment and had recovered their testosterone levels, while nearly 58% remained treatment-free overall. Patients who stopped treatment stayed off therapy for a median of 24.5 months, and nearly 40% were still on a treatment break at the latest follow-up. Importantly, survival outcomes remained encouraging, raising the possibility that carefully selected patients may be able to enjoy extended periods without treatment and its associated side effects.
4. ARACOG: Comparing cognitive effects of darolutamide and enzalutamide
Prostate cancer treatment isn’t only about PSA numbers and scan results. It’s also about how patients feel, think, function, and live day to day. The ARACOG study compared the cognitive effects of darolutamide and enzalutamide, two androgen receptor pathway inhibitors used in prostate cancer treatment. This study is important because some patients report concerns about memory, focus, mental sharpness, and fatigue while on hormone-based therapies.
If one treatment has less impact on cognition for certain patients, that could become an important part of shared decision-making, especially for patients who are working, caregiving, driving, or already concerned about cognitive changes.
Key takeaways: Findings suggest that darolutamide may have less impact on cognitive function than enzalutamide. After 24 weeks of treatment, patients taking darolutamide experienced significantly less decline in cognitive skills compared with those taking enzalutamide. Notably, all patients who switched treatments because of cognitive concerns moved from enzalutamide to darolutamide, further supporting the cognitive benefit seen with darolutamide. These findings may help patients and their doctors weigh potential quality-of-life considerations when choosing between androgen receptor-targeted therapies.
5. ProstACT Global: A new PSMA-targeted radioligand therapy for advanced prostate cancer
Radioligand therapy is quickly becoming one of the most exciting areas of prostate cancer research, and ProstACT Global is evaluating a new treatment called TLX591-Tx for patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC).
What makes this study different is that TLX591-Tx uses an antibody to deliver radiation directly to prostate cancer cells that express PSMA. Researchers hope this approach may allow the treatment to stay attached to tumors longer while limiting radiation exposure to healthy tissues. Another potential advantage is convenience: patients in this study received just two doses of treatment, given two weeks apart.
Key takeaways: The ASCO 2026 update focused on safety and how the treatment moves through the body rather than how well it controls cancer. Researchers found that TLX591-Tx could be combined with standard treatments such as enzalutamide, abiraterone, or docetaxel without any unexpected safety concerns. Imaging studies showed that the treatment remained concentrated in tumors while keeping radiation exposure to important organs below established safety limits.
While it is still too early to know whether TLX591-Tx improves outcomes, these findings support moving forward with the next phase of the trial. For patients, this study represents another step toward more precise, personalized radioligand therapies that may one day offer new treatment options beyond those available today.
Why this matters for patients
Large cancer meetings like ASCO can feel overwhelming, especially when headlines start appearing before patients have a clear explanation of what the research actually means. Not every study will change treatment right away, and early excitement doesn’t always translate into a new standard of care.
These meetings offer an important glimpse into where prostate cancer care is heading:
- More treatment personalization
- Earlier use of intensified therapy for selected patients
- Greater focus on genetic and biomarker testing
- More attention to quality of life and cognitive side effects
- Continued growth of PSMA-targeted radioligand therapy
For patients, the goal is not to become an expert in every abstract. The goal is to know which questions may be worth bringing back to your care team.
Outcomes4Me is here to help you better understand your diagnosis and treatment options. You deserve clear, trustworthy information at every step.
